HCV neutralization goes elite.
Immunity
; 55(2): 195-197, 2022 02 08.
Article
de En
| MEDLINE
| ID: mdl-35139349
ABSTRACT
A vaccine remains the most promising option to eradicate HCV. In this issue of Immunity, Weber et al. identified HCV elite neutralizers, isolated exceptionally potent and broad VH1-69 CD81-binding site neutralizing antibodies that used a shared mode of antigen recognition, and developed a computational approach that predicted mutations relevant to gain-of-function for this bnAb class, which can inform immunogen designs.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Hépatite C
/
Anticorps neutralisants
Limites:
Humans
Langue:
En
Journal:
Immunity
Sujet du journal:
ALERGIA E IMUNOLOGIA
Année:
2022
Type de document:
Article
Pays de publication:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA